Jiangsu Hengrui PharmaceuticalsLtd Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

SHSE:600276 Recent Insider Transactions by Companies or Individuals
Date	Value	Name	Entity	Shares	Max Price
25 Sep 25	SellCN¥1,449,700	Jie Ping Sun	Individual	20,000	CN¥72.49
18 Sep 25	SellCN¥1,456,000	Jie Ping Sun	Individual	20,000	CN¥72.80
09 Sep 25	SellCN¥147,900	Jie Ping Sun	Individual	2,000	CN¥73.95
03 Sep 25	SellCN¥3,232,499	Jie Ping Sun	Individual	45,000	CN¥71.83
02 Sep 25	SellCN¥1,055,350	Jie Ping Sun	Individual	15,000	CN¥70.36
01 Sep 25	SellCN¥1,029,118	Jie Ping Sun	Individual	15,040	CN¥68.43
29 Aug 25	SellCN¥666,800	Jie Ping Sun	Individual	10,000	CN¥66.68
25 Aug 25	SellCN¥660,364	Jie Ping Sun	Individual	10,000	CN¥66.04
22 Aug 25	SellCN¥1,285,700	Jie Ping Sun	Individual	20,000	CN¥64.28
18 Jul 25	SellCN¥2,062,000	Jie Ping Sun	Individual	35,000	CN¥58.91
10 Jul 25	SellCN¥1,731,552	Jie Ping Sun	Individual	30,000	CN¥57.72
09 Jul 25	SellCN¥856,200	Jie Ping Sun	Individual	15,000	CN¥57.08

Insider Trading Volume

Insider Buying: 600276 insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of 600276?
Owner Type	Number of Shares	Ownership Percentage
Individual Insiders	7,843,054	0.118%
Employee Share Scheme	35,700,000	0.539%
Institutions	1,728,582,489	26.1%
General Public	1,968,665,965	29.7%
Private Companies	2,884,149,256	43.5%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 64.89% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
23.2%	Jiangsu Hengrui Medicine Group Co., Ltd.	1,538,184,187	CN¥94.2b	0%	no data
14.4%	Tibet Dagze Huixin Investment Management Partnership (Limited Partnership)	952,752,304	CN¥58.3b	0%	no data
5.88%	Hong Kong Exchanges and Clearing Limited	389,525,860	CN¥23.8b	0%	3.29%
3.09%	China National Pharmaceutical Group Corporation	204,669,209	CN¥12.5b	-8.2%	no data
2.74%	Qingdao Bosentai Investment Partnership Enterprise (Limited Partnership)	181,506,156	CN¥11.1b	-0.18%	no data
1.66%	Lianyungang Financial Holding Group Co., Ltd.	109,787,876	CN¥6.7b	-1.81%	no data
1.44%	China Securities Finance Corporation Limited	95,399,822	CN¥5.8b	0%	0.89%
1.36%	China Universal Asset Management Company Ltd.	90,311,019	CN¥5.5b	-0.03%	1.92%
1.32%	China Asset Management Co. Ltd.	87,616,096	CN¥5.4b	7.2%	0.6%
1.2%	Huatai-PineBridge Fund Management Co., Ltd.	79,499,531	CN¥4.9b	3.17%	1.0%
1.19%	E Fund Management Co., Ltd.	79,036,142	CN¥4.8b	0%	0.52%
1.05%	Zhong Ou Fund Management Co., Ltd	69,779,796	CN¥4.3b	0%	1.9%
0.97%	ICBC Credit Suisse Fund Management Co., Ltd	64,049,049	CN¥3.9b	0%	2.33%
0.82%	GIC Private Limited	54,422,600	CN¥3.3b	5.31%	0.8%
0.65%	Harvest Fund Management Co. Ltd.	42,808,327	CN¥2.6b	0%	0.55%
0.63%	Capital Research and Management Company	41,464,135	CN¥2.5b	-6.25%	0.02%
0.54%	Jiangsu Hengrui Medicine Co., Ltd., ESOP	35,700,000	CN¥2.2b	0%	no data
0.48%	GF Fund Management Co., Ltd.	31,607,702	CN¥1.9b	0%	0.43%
0.45%	Yinhua Fund Management Co., Ltd.	29,784,230	CN¥1.8b	-0.25%	1.39%
0.39%	BlackRock, Inc.	25,989,755	CN¥1.6b	13.2%	no data
0.31%	Guotai Asset Management Company Limited	20,586,279	CN¥1.3b	-0.03%	0.57%
0.31%	HuaAn Fund Management Company Ltd.	20,396,227	CN¥1.2b	0%	0.55%
0.29%	Wellington Management Group LLP	19,012,140	CN¥1.2b	38.9%	0.03%
0.28%	The Vanguard Group, Inc.	18,233,683	CN¥1.1b	1.89%	no data
0.25%	Penghua Fund Management Co., Ltd.	16,730,232	CN¥1.0b	0%	0.66%

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/11/12 16:57
End of Day Share Price	2025/11/12 00:00
Earnings	2025/09/30
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Jiangsu Hengrui Pharmaceuticals Co.,Ltd is covered by 46 analysts. 25 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Bo Li	BofA Global Research
Yanan Hou	Bohai Securities Co., Ltd.
Shun Kei Law	CCB International Securities Limited